MX2012003155A - Profarmacos de guanfacina. - Google Patents

Profarmacos de guanfacina.

Info

Publication number
MX2012003155A
MX2012003155A MX2012003155A MX2012003155A MX2012003155A MX 2012003155 A MX2012003155 A MX 2012003155A MX 2012003155 A MX2012003155 A MX 2012003155A MX 2012003155 A MX2012003155 A MX 2012003155A MX 2012003155 A MX2012003155 A MX 2012003155A
Authority
MX
Mexico
Prior art keywords
guanfacine
prodrugs
disorder
adhd
pharmacokinetics
Prior art date
Application number
MX2012003155A
Other languages
English (en)
Inventor
Bernard T Golding
Robert G Tyson
Richard Franklin
Rhys Whomsley
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Publication of MX2012003155A publication Critical patent/MX2012003155A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se proporcionan os profármacos de guanfacina con aminoácidos o péptidos cortos, composiciones farmacéuticas que contienen dichos profármacos y un método para proporcionar un beneficio terapéutico en el tratamiento de ADHD/QDD (un trastorno por déficit de atención con hiperactividad y trastorno de oposición desafiante) con profármacos de guanfacina. Asimismo, en la presente se proporcionan métodos para minimizar o evitar los efectos secundarios adversos asociados con la administración de la guanfacina, así como para mejorar la farmacocinética de la guanfacina.
MX2012003155A 2009-09-15 2010-09-15 Profarmacos de guanfacina. MX2012003155A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24250709P 2009-09-15 2009-09-15
GBGB0916163.9A GB0916163D0 (en) 2009-09-15 2009-09-15 Prodrugs of guanfacine
PCT/GB2010/051544 WO2011033296A1 (en) 2009-09-15 2010-09-15 Prodrugs of guanfacine

Publications (1)

Publication Number Publication Date
MX2012003155A true MX2012003155A (es) 2012-05-22

Family

ID=41277730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003155A MX2012003155A (es) 2009-09-15 2010-09-15 Profarmacos de guanfacina.

Country Status (13)

Country Link
US (2) US20120178666A1 (es)
EP (1) EP2477962A1 (es)
JP (1) JP2013504614A (es)
KR (1) KR20120089806A (es)
CN (1) CN102498094A (es)
AU (1) AU2010297024A1 (es)
BR (1) BR112012005598A2 (es)
CA (1) CA2774147A1 (es)
EA (1) EA201270419A1 (es)
GB (1) GB0916163D0 (es)
IL (1) IL218683A0 (es)
MX (1) MX2012003155A (es)
WO (1) WO2011033296A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511037B2 (en) 2010-04-23 2016-12-06 Genco Sciences Llc Compositions for reduction of side effects
US10463633B2 (en) 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
KR20130105655A (ko) 2010-09-15 2013-09-25 샤이어 엘엘씨 구안파신의 프로드러그
WO2012046062A1 (en) * 2010-10-05 2012-04-12 Shire, Llc Use of prodrugs to avoid gi mediated adverse events
CN103058890A (zh) * 2012-12-27 2013-04-24 郑州大明药物科技有限公司 盐酸胍法辛的制备方法
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
RU2016147009A (ru) * 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Композиции с пролонгированным высвобождением в виде суспензии
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10285908B2 (en) 2014-07-30 2019-05-14 Sun Pharmaceutical Industries Ltd Dual-chamber pack
US10022341B2 (en) 2014-12-02 2018-07-17 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
WO2020106454A2 (en) * 2018-11-07 2020-05-28 Regents Of The University Of Minnesota Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1298112A (en) * 1969-02-20 1972-11-29 Wander Ag Dr A Phenyl acetyl guanidine derivatives
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
DE19622370A1 (de) * 1996-06-04 1997-12-11 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0837055A1 (en) * 1996-07-30 1998-04-22 Hoechst Aktiengesellschaft Substituted Indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic and medicaments containing them
FR2786182B1 (fr) * 1998-11-24 2001-01-12 Hoechst Marion Roussel Inc Nouveaux derives d'acylguanidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
PT1294358E (pt) 2000-06-28 2004-12-31 Smithkline Beecham Plc Processo de moagem por via humida
KR20080041669A (ko) * 2005-07-28 2008-05-13 샤이어 엘엘씨 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물
US20070281996A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine prodrugs, compositions and uses thereof

Also Published As

Publication number Publication date
EP2477962A1 (en) 2012-07-25
CA2774147A1 (en) 2011-03-24
AU2010297024A1 (en) 2012-03-29
WO2011033296A1 (en) 2011-03-24
JP2013504614A (ja) 2013-02-07
BR112012005598A2 (pt) 2016-06-14
CN102498094A (zh) 2012-06-13
KR20120089806A (ko) 2012-08-13
GB0916163D0 (en) 2009-10-28
EA201270419A1 (ru) 2012-08-30
US20110065796A1 (en) 2011-03-17
IL218683A0 (en) 2012-05-31
US20120178666A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
MX2012003155A (es) Profarmacos de guanfacina.
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
EP3192526A3 (en) Exosomes for delivery of biotherapeutics
NZ724593A (en) Anti-cd70 antibody drug conjugates
MY167804A (en) Treatment of degenerative joint disease
UA101497C2 (ru) Конъюгаты фактора ix с увеличенным временем полужизни
WO2009105774A3 (en) Amino acid inhibitors of cytochrome p450
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
WO2012176172A3 (en) Combination therapy with psd-95 inhibitor for ischemia
IN2014DN00101A (es)
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
EA201490760A1 (ru) R(+)-n-метилпропаргиламиноиндан
MX2012014432A (es) Terapia de combinacion con lisdexanfetamina y guanfacina de liberacion prolongada.
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
EP2061456A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING P450 CYTOCHROME
EA201300990A1 (ru) Парентеральное введение тапентадола
MX2014002062A (es) Nanoparticulas de peptido y usos de las mismas.
EA201491258A1 (ru) Самосшивающие катетеры
PH12014502682B1 (en) Manufacture of degarelix
BR112013005711A2 (pt) método para tratar um tumor, mutante, molécula de ácido nucleico isolada, construção de expressão, composição, e, método para administrar uma terapia
MX366347B (es) Aislamiento de mutantes mejoradores del trafico de la proteina de administracion de farmaco.
TW200609200A (en) Preparation of levalbuterol hydrochloride
EP3309555A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин

Legal Events

Date Code Title Description
FA Abandonment or withdrawal